Orthocell’s single-stage dental implant study has completed treatment of last patient, it is designed to further authenticate the flexibility of CelGro for soft tissue repair and dental bone. To generate further data and educate surgeons on the benefits of using CelGro it represents a key milestone in Orthocell’s marketing strategy. In 2Q CY2019 the release of top line results is expected. The treatment process customarily requires two surgical procedures.
Followed by a second re-entry surgery, to insert the implant support and dental crown, up to 3-6 months later, where patients receive an initial implant placement traditional dental implant procedure are often performed in two-stages. To fill the missing tooth while bone healing is underway patients can be left without a temporary crown which creates challenges for patients both functionally and visually. For some patients advances in technology allow the potential for a single-stage procedure which removes the need for re-entry surgery, potentially reducing the total costs to patients and the health care system and accelerating the healing process.
In in collaboration with leading West Australian oral’s Dr. Brent Allan of St. John of God Subiaco Hospital and maxillofacial surgeon Professor Ming Hao Zheng of the University of Western Australia the single-stage performance study is being undertaken. There are more than 1 million dental implant procedures per year in Italy alone as shown by dental implants are an effective and rapidly growing treatment and industry research, where approximately 60% of procedures require the use of a collagen membrane.
On the solid wharf and integration between the implant and dental bone is on what the success of dental implants relies. In enabling high-quality bone repair and preventing tissue in growth, Celgro plays an important role in this procedure. Celgro assists surgeons in delivering improved patient outcomes via tissue integration qualities, superior handling characteristic and improving bone quality demonstrated by clinical trials compared to the market leading comparative dental product.
To utilize the supplementary marketing data generated from the single-stage performance study and guide superior quality bone formation, Orthocell intends to leverage CelGro’s ability to further position CelGro as the best in class collagen membrane for soft tissue repair and dental bone. The study highlights the potential to extend Orthocell’s innovative dental product range and underpins the versatility and compatibility of CelGro platform technology.
Orthocell Limited (ASX: OCC) traded at a market price of $0.215 as at November 28, 2018 which is near its 52-week low.